Children's compliance with allergen immunotherapy according to administration routes

Pajno, Giovanni Battista; Vita, Daniela De; Caminiti, Lucia; Arrigo, T; Lombardo, Fortunato; Incorvaia, Cristoforo; Barberio, G

doi:10.1016/j.jaci.2005.07.034

Cited by 104 publications

(90 citation statements)

References 9 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Factors that have been shown to be important for adherence to AIT include cost; inconvenience; feelings of inefficacy; adverse events (AEs); patient, parent and physician education and number of followup visits [21,32]. Lack of adherence to SLIT may also be caused by the incorrect perception that upon improvement in allergic symptoms, there is no further need to continue therapy [19].…”

Section: Abstract: 5-grass-pollen Tablet • Allergic Rhinitis • Allergmentioning

confidence: 99%

Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience

Didier

Wahn

Horak

et al. 2014

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

OralairÒ (OA) (Stallergenes, Antony, France) is a unique pre-and co-seasonal 5-grass-pollen sublingual immunotherapy tablet launched in 2008, and now approved in 31 countries worldwide for the treatment of grass-pollen allergic rhinitis and rhinoconjunctivitis. OA is the first oral treatment with a consistent, well-balanced allergen extract that mimics natural exposure and sensitization. A wealth of data exists from over 5 years of clinical and realworld experience demonstrating the efficacy and safety of OA for grass-pollen-allergy treatment. OA is highly effective from the first pollen season in all patient subgroups, including children and those with comorbid mild asthma, irrespective of sensitization status and symptom severity. OA also has sustained long-term benefits for symptom control and quality of life. This article provides an overview of the pharmacodynamics and pharmacology of OA; its efficacy, safety, tolerability and cost-effectiveness for the treatment of allergic rhinitis and rhinoconjunctivitis and its role in clinical practice. Allergic rhinitis (AR) is a common chronic inflammatory illness, characterized by rhinorrhea, nasal congestion, sneezing, nasal and ocular pruritis and watery eyes [1]. Inhalation of allergens by sensitized individuals triggers the IgE-mediated release of inflammatory mediators and cytokines, leading to a rapid appearance of symptoms [2]. AR has historically been classified as 'seasonal' or 'perennial' depending on whether symptoms occur with seasonal exposure to aeroallergens or are present throughout the year. Seasonal AR is most commonly attributed to plant pollen and other outdoor allergens, while perennial AR is associated with indoor allergens, such as dust mites, mold, cockroaches and pet dander, although it can also be associated with pollen in areas where this is prevalent year-round [3,4].In 2001, the WHO-sponsored Allergic Rhinitis and its Impact on Asthma meeting produced guidelines proposing an alternative classification of the condition into 'intermittent' or 'persistent' AR, and grading symptoms as 'mild' or 'moderate/severe' [5]. Globally, the prevalence of seasonal ('hay fever') and perennial AR ranges from 7 to 42 and 1 to 13%, respectively, with the former being more common in children than adults [6]. The length of exposure to seasonal allergens is dependent on geographic location and climatic conditions [4]; in Europe, the main pollen season typically occurs from March to July, with slight variations according to latitude [7].Approximately 500 million people worldwide [6], including an estimated 30-60 million in the USA [4] 1309Drug Profile suffer from AR, and its prevalence is increasing in most countries [2]. It is estimated that from 10 to 30% of adults and up to 40% of the pediatric population have AR [3,9]. While AR does not directly lead to mortality, it places a considerable burden on affected individuals, who often have a reduced quality of life (QoL), compared with non-sufferers [10]. The physical symptoms of AR can cause sleep disturbance...

show abstract

Section: Abstract: 5-grass-pollen Tablet • Allergic Rhinitis • Allergmentioning

confidence: 99%

Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience

Didier

Wahn

Horak

et al. 2014

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

show abstract

“…Wäh-rend zwei Studien [10,13] eine Compliance bei SLIT von ca. 80% finden, verzeichnen Lombardi et al 2004 [8] eine Compliance von 97,3%.…”

Section: Diskussionunclassified

Persistenz und Frequenz von Verordnungen im Bereich der subkutanen allergenspezifischen Immuntherapie (SCIT) bei GKV-Patienten in Deutschland

2009

View full text Add to dashboard Cite

The analysis of this secondary dataset has found that nonpersistence may jeopardize the therapy according to guidelines to a greater extent than expected from the literature. Except for one allergen extract the differentiation between long-term and short-term SCIT seems diffuse. Packages for consecutive treatment are used not only in long-term SCIT, but also in short-term SCIT regimens, if they are available. The analysis provides first hints that a shorter therapy regimen supports persistence of SCIT during the 2nd and 3rd year of therapy.

show abstract

“…Eine andere Untersuchung fand bei einer sehr großen Patientenzahl einen Abbruch der SLIT über 3 Jahre bei etwa jedem 5. Patienten, womit diese Rate doppelt so hoch war wie bei der SCIT [189]. Es ergeben sich deutliche Unterschiede, ob Daten im Rahmen von klinischen oder in "Real-life-Studien" erhoben wurden.…”

Section: Durchführung Und Applikationsformenunclassified

Allergenspezifische Immuntherapie bei IgE-vermittelten Erkrankungen im Kindes- und Jugendalter

Szépfalusi

Horák

Eiwegger

et al. 2018

Monatsschr Kinderheilkd

View full text Add to dashboard Cite

Children's compliance with allergen immunotherapy according to administration routes

Cited by 104 publications

References 9 publications

Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience

Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience

Persistenz und Frequenz von Verordnungen im Bereich der subkutanen allergenspezifischen Immuntherapie (SCIT) bei GKV-Patienten in Deutschland

Allergenspezifische Immuntherapie bei IgE-vermittelten Erkrankungen im Kindes- und Jugendalter

Contact Info

Product

Resources

About